FINNENCE ▪ THE WIRE FILE
THE WIRE · № 79223
Video▲ Bullish
J&J raises its forecast again. CFO Joe Wolk on what's driving it
KINDVideo
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Raised guidance on oncology and immunology growth signals resilient pharma demand.
J&J raises outlook on drug strength
CATALYST TO WATCH
Next earnings and drug pipeline news
MAIN RISK
Stelara exclusivity loss drags revenue
FULL DISPATCH
Johnson & Johnson raised its full-year forecast again on October 13, 2026, and CFO Joe Wolk tells Yahoo Finance's Julie Hyman that pharmaceuticals led the way, with oncology up 17% and immunology returning to growth despite losing exclusivity on Stelara. Wolk explains why MedTech growth of about 2.5
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTJohnson & Johnson · JNJ
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Widex Allure AI RIC with Clarity Boost Now Available in the U.S. and Major European Countries, Redefining How AI Supports Natural Hearing2026-10-14 07:00 UTC
Widex Allure AI RIC with Clarity Boost Now Available in the U.S. and Major European Countries, Redefining How AI Supports Natural Hearing2026-10-14 07:00 UTC
→CORRELATIONshares Healthcare
SciBase secures first payer coverage with Highmark, marking a major commercial inflection point2026-10-14 07:26 UTC
SciBase secures first payer coverage with Highmark, marking a major commercial inflection point2026-10-14 07:26 UTC
→CORRELATIONshares Healthcare
Kedrion: at ESID 2026, experts call for earlier diagnosis and greater awareness as Secondary Immunodeficiencies continue to rise2026-10-14 08:00 UTC
Kedrion: at ESID 2026, experts call for earlier diagnosis and greater awareness as Secondary Immunodeficiencies continue to rise2026-10-14 08:00 UTC
→CORRELATIONshares Healthcare
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda2026-10-14 08:07 UTC
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda2026-10-14 08:07 UTC
←CORRELATIONshares JNJ, Healthcare
Johnson & Johnson CFO Joseph Wolk: 'You can't heap enough praise on the pharma unit'2026-10-13 16:30 UTC
Johnson & Johnson CFO Joseph Wolk: 'You can't heap enough praise on the pharma unit'2026-10-13 16:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.